Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,717 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01).
Wang Z, Wu L, Li B, Cheng Y, Li X, Wang X, Han L, Wu X, Fan Y, Yu Y, Lv D, Shi J, Huang J, Zhou S, Han B, Sun G, Guo Q, Ji Y, Zhu X, Hu S, Zhang W, Wang Q, Jia Y, Wang Z, Song Y, Wu J, Shi M, Li X, Han Z, Liu Y, Yu Z, Liu AW, Wang X, Zhou C, Zhong D, Miao L, Zhang Z, Zhao H, Yang J, Wang D, Wang Y, Li Q, Zhang X, Ji M, Yang Z, Cui J, Gao B, Wang B, Liu H, Nie L, He M, Jin S, Gu W, Shu Y, Zhou T, Feng J, Yang X, Huang C, Zhu B, Yao Y, Tang X, Yu J, Maher E, Feng H, Yao S, Keegan P, Wang J. Wang Z, et al. Among authors: gu w. J Clin Oncol. 2023 Jan 20;41(3):651-663. doi: 10.1200/JCO.22.00727. Epub 2022 Oct 7. J Clin Oncol. 2023. PMID: 36206498 Free PMC article. Clinical Trial.
Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial.
Zhang Z, Yang Y, Lu P, Li X, Chang J, Zheng R, Zhou L, Chen S, Chen X, Ren B, Gu W, Jiang X, Peng J, Huang M, Feng G, Shen P, Zhang Q, Zhang B, Huang Y, He J, Chen Y, Cao J, Wang H, Li W, Wan H, Nan K, Liao Z, Zhang C, Lin Z, Zhong D, Xu Q, Liu H, Sun T, Deng Y, Zhang L. Zhang Z, et al. Among authors: gu w. Ann Transl Med. 2020 Mar;8(5):234. doi: 10.21037/atm.2019.12.158. Ann Transl Med. 2020. PMID: 32309381 Free PMC article.
Severe eosinophilic asthma in Chinese C-BIOPRED asthma cohort.
Zhang Q, Fu X, Wang C, Shen H, Zhu L, Shi G, Qiu Z, Wen Z, Gu W, Luo W, Zhao L, Chen Y, Lim S, Xiao C, Kang J, Zhang Y, Huang M, Xu J, Huang K, Li Q, Zhang X, Zhao J, Liu X, Sun S, Tang H, He B, Cai S, Chen P, Wei C, Wang G, Chen P, Xie L, Lin J, Tang Y, Han Z, Chung KF, Zhong N; C-BIOPRED consortium. Zhang Q, et al. Among authors: gu w. Clin Transl Med. 2022 Feb;12(2):e710. doi: 10.1002/ctm2.710. Clin Transl Med. 2022. PMID: 35184418 Free PMC article. No abstract available.
Influence of sex, cigarette smoking and airway inflammation on treatable traits in CBIOPRED severe asthma.
Dong C, Yang X, Luo W, Fan E, Assam NP, Kang J, Zhang Y, Huang M, Xu J, Huang K, Li Q, Zhang X, Zhao J, Liu X, Sun S, Tang H, He B, Cai S, Chen P, Wei C, Wang G, Chen P, Xie L, Lin J, Tang Y, Han Z, Fu X, Wang C, Shen H, Jin M, Zhu L, Shi G, Qiu Z, Wen Z, Gu W, Chung KF, Zhang Q, Zhong N; C‒BIOPRED consortium. Dong C, et al. Among authors: gu w. Clin Transl Allergy. 2022 Sep 15;12(9):e12189. doi: 10.1002/clt2.12189. eCollection 2022 Sep. Clin Transl Allergy. 2022. PMID: 36176735 Free PMC article. No abstract available.
Eligibility of C-BIOPRED severe asthma cohort for type-2 biologic therapies.
Deng Z, Jin M, Ou C, Jiang W, Zhao J, Liu X, Sun S, Tang H, He B, Cai S, Chen P, Wu P, Liu Y, Kang J, Zhang Y, Huang M, Xu J, Huang K, Li Q, Zhang X, Fu X, Wang C, Shen H, Zhu L, Shi G, Qiu Z, Wen Z, Wei X, Gu W, Wei C, Wang G, Chen P, Xie L, Lin J, Tang Y, Han Z, Chung KF, Zhang Q, Zhong N; C-BIOPRED Consortium. Deng Z, et al. Among authors: gu w. Chin Med J (Engl). 2023 Jan 20;136(2):230-232. doi: 10.1097/CM9.0000000000002556. Chin Med J (Engl). 2023. PMID: 36752798 Free PMC article. No abstract available.
5,717 results